Please login to the form below
Althea
This page shows the latest Althea news and features for those working in and with pharma, biotech and healthcare.
Charity launches real-world medical cannabis study
Project TWENTY21 will be run by a working group drawn from the United Patients Alliance (UPA), several academic researchers and medical cannabis companies including Althea which recently entered the UK market.
Latest news
-
GW Pharma's cannabis-based medicine to be tested in dementia
Just earlier this week medical cannabis firm Althea announced it is to enter the UK market and will start supplying products as of next month.
-
Medicinal cannabis firm Althea enters UK market
It will start supplying products next month. Australia’s Althea Group has become one the first medical cannabis companies to enter the UK market since the government made these products available ... Given the current controversy, Althea’s launch
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Pharma deals during March 2013
225. Althea Technologies/ Ajinomoto. Acquisition. CMO - biopharmaceutical development and manufacturing services.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Ketchum appoints Conor Nash as global chief financial officer and chief operating officer
PMHub
BOLDSCIENCE
We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
